| Keith Weston, MD | |
|
5 Alumni Drive, Anesthesia Dept., Exeter, NH 03833-2128 | |
| (603) 580-6624 | |
| (603) 580-6620 |
| Full Name | Keith Weston |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 5 Alumni Drive, Exeter, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588604235 | NPI | - | NPPES |
| 050081232 | Other | RAILROAD MEDICARE | |
| 30201491 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 9758 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Keith Weston, MD Po Box 655, Exeter, NH 03833-0655 Ph: (603) 580-6624 | Keith Weston, MD 5 Alumni Drive, Anesthesia Dept., Exeter, NH 03833-2128 Ph: (603) 580-6624 |
News Archive
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC).
Cardiorespiratory fitness is associated with reduced metabolic syndrome risk among smokers, according to researchers from The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.
Ethicon, Inc., a Johnson & Johnson company and a worldwide leader in surgical care, and Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT), today announced a definitive merger agreement whereby Ethicon will acquire Acclarent in an all-cash transaction for approximately $785 million net of estimated cash on hand at time of closing.
White matter abnormalities in the right temporal lobe may be a marker of genetic risk for bipolar disorder, results from a US study suggest.
› Verified 5 days ago
Young S Park, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5 Alumni Drive, Anesthesia Department, Exeter, NH 03833 Phone: 603-580-6624 Fax: 603-580-6620 | |
Sean Burns, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5 Alumni Dr, Anesthesia Dept., Exeter, NH 03833 Phone: 603-580-6624 Fax: 603-580-6620 | |
Dr. Julie Snell Rose, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5 Alumni Dr, Exeter, NH 03833 Phone: 757-285-6733 | |
Dr. Karla Greco, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5 Alumni Dr, Exeter, NH 03833 Phone: 603-580-6624 Fax: 603-580-6961 | |
Joanna Thomas, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5 Alumni Dr, Exeter, NH 03833 Phone: 603-580-6624 Fax: 603-580-6620 | |
Charles D London, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5 Alumni Dr, Anesthesia Dept., Exeter, NH 03833 Phone: 603-580-6624 Fax: 603-580-6620 |